MEDTECH INSIGHT
CITELINE COMMERCIAL

17 Jul 2019 | **News**

QUOTED. 17 July 2019. Peter Shearstone.

by

Thermo Fisher Scientific's Peter Shearstone is urging fellow *in vitro* diagnostic firms to play in the US FDA's Case for Quality Voluntary Improvement Program (CFQ VIP). See what he said here.

"[The IVD industry] has to absolutely get away from being a reactive business. I think we thrive on – maybe as human beings – the excitement of problem-solving and saving the day, but the reality of it is, we have to do a lot more proactive things to avoid the mistakes – the errors – from happening in the first place. I look at ... CFQ VIP as a way to move the thinking toward proactivity and getting out of the routine of always going from crisis to crisis." – Peter Shearstone, VP of global quality assurance and regulatory affairs, Thermo Fisher Scientific Inc.

- Find out more: *Thermo Fisher VP Wants More IVD Firms Involved In FDA's Manufacturing Maturity Program (Even Though His Company Isn't)*